Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
Brief
On 27/02/2025, the "Medicines and Healthcare products Regulatory Agency (MHRA)" issued an update regarding "mRESVIA RSV vaccine approved to protect patients aged 60 and over". The vaccine works by preparing the body's immune system to defend itself against respiratory syncytial virus (RSV), reducing the risk of lower respiratory tract disease. It has been shown to be safe and effective, with a 79% reduction in the risk of getting lower respiratory tract disease caused by RSV among participants aged 60 or older.
Highlights content goes here...
Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
